5年阴跌200亿，上海抗癌药明星换帅

Core Viewpoint - WuXi AppTec's subsidiary, WuXi Biologics, has undergone a management change with Tian Feng appointed as the new CEO, following the resignation of Liu Min, who served for only 1.5 years. This change comes as the company faces significant challenges in commercializing its CAR-T therapy product, Benauda, which has seen a decline in market performance despite being a once-promising player in the cell therapy sector [2][5][9]. Management Changes - Tian Feng has been appointed as the new CEO and Executive Director, while Liu Cheng has been promoted to Chairman of the Board. This marks the third CEO change in 18 months for WuXi Biologics [2][5]. - Tian Feng, aged 48, has over 20 years of experience in the biopharmaceutical industry, having previously held senior positions at multinational pharmaceutical companies and successfully introduced products into the national medical insurance system [5][8]. - Liu Cheng, the new Chairman, is a seasoned technical expert with over 300 patents and significant experience in CAR-T technology, although he will not be involved in daily operations [8][9]. Product and Market Challenges - WuXi Biologics' core product, Benauda, has been included in the first batch of commercial insurance innovative drug directories, which may lead to a price reduction from 1 million RMB to around 100,000 RMB per injection [4][9]. - The company has faced substantial losses, with annual losses ranging from 600 million to 800 million RMB since 2021, totaling approximately 3 billion RMB over five years, leading to a significant drop in market capitalization [9][19]. - Benauda, approved in 2021, has only benefited around 600 patients, with total sales exceeding 600 million RMB, but the high costs of research and commercialization have made it difficult for the company to sustain operations [11][19]. Financial and Operational Strategies - The company has implemented cost-cutting measures, reducing its workforce from 534 to 281 employees and decreasing operational expenses by 20-40% in various departments [24][26]. - WuXi Biologics aims to lower production costs by promoting domestic sourcing of raw materials and expanding its research pipeline to explore new opportunities [20][22]. - The company has made progress in the blood cancer field and is advancing research in solid tumors, while also securing multiple technology agreements that could generate significant revenue [22]. Future Outlook - The CAR-T therapy market in China is projected to grow from 200 million RMB in 2021 to 8 billion RMB by 2025, with expectations of reaching 28.9 billion RMB by 2030, although achieving these targets may be challenging [15][19]. - The new management team, led by Tian Feng, is tasked with navigating through the current difficulties and positioning the company for future growth and potential capital injections [26].